← Back to Patent Explorer
US4058602A Expired / Lapsed US ⏱️ 0.0 years remaining

Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine

Assignee: United States Department of Health and Human Services
•
Filing: 1976-08-09
•
Granted: 1977-11-15
•
Expires: 1996-08-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The compound 5,6-dihydro-5-azacytidine, 5AC[H], and non-toxic acid addition salts such as the hydrochloride, together with its preparation from 5-azacytidine (5-AC) by reduction of the 5,6-double bond of 5-AC with an alkali metal borohydride such as sodium borohydride. Additionally, 5,6-dihydro-5-azacytidine, 5AC[H], has antitumor activity for murine leukemia systems L1210 and P388 as an injectable. In comparison with the parent compound, 5-AC, the antitumor activity is comparable and 5AC[H] exhibits a more favorable therapeutic index. It also has better solution stability over a broad pH range. A structure for the HCl salt is given below. <IMAGE>

Inventors

  • 👤 John A. Beisler
  • 👤 Mohamed M. Abbasi
  • 👤 John S. Driscoll

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 17:26
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/12

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 44 words
5,6dihydro-5 -azacytidine and a non-toxic acid addition salt thereof wherein such salt is selected from a group consisting of non-toxic mineral acid salts and salts of organic acids selected from one member of a group consisting of maleate, tartrate, citrate, acetate, benzoate, and borate.
Claim 2
Dependent Claim 44 words
5,6dihydro-5 -azacytidine and a non-toxic acid addition salt thereof wherein such salt is selected from a group consisting of non-toxic mineral acid salts and salts of organic acids selected from one member of a group consisting of maleate, tartrate, citrate, acetate, benzoate, and borate.
Claim 3
Dependent Claim 39 words
A process of reducing 5-azacytidine utilizing an alkali metal borohydride in hexamethylphosphoramide solution to produce the compound 5,6-dihydro-5-azacytidine as a boron complex and subsequently hydrolyzing said boron complex with a mineral acid to produce 5,6-dihydro-5-azacytidine as the acid salt.
Claim 4
Dependent Claim 39 words
A process of reducing 5-azacytidine utilizing an alkali metal borohydride in hexamethylphosphoramide solution to produce the compound 5,6-dihydro-5-azacytidine as a boron complex and subsequently hydrolyzing said boron complex with a mineral acid to produce 5,6-dihydro-5-azacytidine as the acid salt.
Claim 5
Dependent Claim 11 words
The process of claim 2 wherein the acid is hydrochloric acid.
Claim 6
Independent Claim 80 words
A method of inhibiting leukemia L1210 and P388 in mice which comprises utilizing an effective amount of 5,6-dihydro-5-azacytidine as an injectable in a dosage regimen of 6 mg/kg - 600 mg/kg of body weight of the compound 5,6-dihydro-5-azacytidine and a non-toxic acid addition salt thereof wherein such salt is selected from a group consisting of non-toxic mineral acid salts and salts of organic acids selected from one member of a group consisting of maleate, tartrate, citrate, acetate, benzoate, and borate.
Claim 7
Independent Claim 80 words
A method of inhibiting leukemia L1210 and P388 in mice which comprises utilizing an effective amount of 5,6-dihydro-5-azacytidine as an injectable in a dosage regimen of 6 mg/kg - 600 mg/kg of body weight of the compound 5,6-dihydro-5-azacytidine and a non-toxic acid addition salt thereof wherein such salt is selected from a group consisting of non-toxic mineral acid salts and salts of organic acids selected from one member of a group consisting of maleate, tartrate, citrate, acetate, benzoate, and borate.
Claim 8
Dependent Claim 10 words
The method of claim 4 wherein leukemia L1210 is inhibited.
Claim 9
Dependent Claim 10 words
The method of claim 4 wherein leukemia P388 is inhibited.

References Cited (Backward Citations)

US3171833A Cited
US3221010A Cited
US3462416A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-11-14 1981-05-16 1981-11-15 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-11-14 1985-05-16 1985-11-15 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-11-14 1989-05-16 1989-11-15 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag